JD Vance Predicts: Wall Street vs. Trump & Your Money

Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.

Get your free guide NOW before it's too late.

Sally Jackson Biography and Net Worth

Sr. VP of Global Communications & CEO Office of GSK

Sally was appointed Senior Vice President, Global Communications and CEO Office and a member of the GSK Leadership Team (GLT) in March 2019.

She leads Communications and Government Affairs globally and is also the CEO’s Chief of Staff. In this role she led the development and embedding of GSK’s Ahead Together purpose, strategy and culture.

Prior to this, she was Senior Vice President, Office of the CEO and CFO where she supported development and implementation of strategy and co-led the integration team for GSK’s 2014/15 three-part transaction with Novartis. She previously served as Head of Investor Relations.

Sally joined the company in 2001 in Portfolio Analytics in R&D and holds a first-class degree in Natural Sciences from the University of Cambridge.

How do I contact Sally Jackson?: The corporate mailing address for Ms. Jackson and other GSK executives is 980 GREAT WEST ROAD, BRENTFORD X0, TW8 9GS. GSK can also be reached via phone at 442080475000 and via email at [email protected]. Learn More on Sally Jackson's contact information.
Has Sally Jackson been buying or selling shares of GSK?: Sally Jackson has not been actively trading shares of GSK over the course of the past ninety days. Learn More on Sally Jackson's trading history.
Who are GSK's active insiders?: GSK's insider roster includes Sally Jackson (Sr. VP of Global Communications & CEO Office), Iain Mackay (CFO & Exec. Director ), and Emma Walmsley (CEO & Director ). Learn More on GSK's active insiders.
Are insiders buying or selling shares of GSK?: During the last year, GSK insiders bought shares 1 times. They purchased a total of 2,791,930 shares worth more than $22,335,440.00. The most recent insider tranaction occured on September, 27th when Major Shareholder Plc Gsk bought 2,791,930 shares worth more than $22,335,440.00. Insiders at GSK own 10.0% of the company. Learn More about insider trades at GSK.
Information on this page was last updated on 9/27/2024.

Sally Jackson Insider Trading History at GSK

Sally Jackson Buying and Selling Activity at GSK

GSK Company Overview

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Today's Range

Now: $33.35

$32.83

$33.50

50 Day Range

MA: $39.08

$33.35

$44.09

2 Week Range

Now: $33.35

$32.83

$45.92

Volume

13,747,891 shs

Average Volume

7,092,211 shs

Market Capitalization

$69.12 billion

P/E Ratio

21.66

Dividend Yield

4.62%

Beta

0.66